lidocaine has been researched along with Blood Poisoning in 17 studies
Lidocaine: A local anesthetic and cardiac depressant used as an antiarrhythmia agent. Its actions are more intense and its effects more prolonged than those of PROCAINE but its duration of action is shorter than that of BUPIVACAINE or PRILOCAINE.
lidocaine : The monocarboxylic acid amide resulting from the formal condensation of N,N-diethylglycine with 2,6-dimethylaniline.
Excerpt | Relevance | Reference |
---|---|---|
"Lidocaine (Lido) is reported to suppress inflammatory responses and exhibit a therapeutic effect in models of cecal ligation and puncture (CLP)-induced acute lung injury (ALI)." | 7.85 | RAGE deficiency attenuates the protective effect of Lidocaine against sepsis-induced acute lung injury. ( Jiang, X; Li, X; Liao, C; Liu, M; Song, D; Zhang, Z; Zhou, J, 2017) |
"The animals were randomly allocated to one of five groups (n = 8 each): hamsters undergoing sham laparotomy alone and receiving saline infusion (Sham group), those undergoing cecal ligation with puncture (CLP) and receiving an infusion of saline (Sepsis group), those undergoing sham laparotomy and receiving infusion of lidocaine, 2 mg/kg/hr (Sham-LID group), those undergoing CLP and receiving infusion of lidocaine, 1 mg/kg/hr (Sepsis-LID 1 group), and those undergoing CLP and receiving infusion of lidocaine, 2 mg/kg/hr (Sepsis-LID 2 group)." | 7.70 | Lidocaine attenuates sepsis-induced diaphragmatic dysfunction in hamsters. ( Kagawa, T; Kodama, S; Maekawa, N; Mikawa, K; Nishina, K; Obara, H, 2000) |
"The monoethylglycinexylidide (MEGX) test was carried out on days 1-10 after admittance to the intensive care unit." | 6.69 | The monoethylglycinexylidide (MEGX) test as a marker of hepatic dysfunction in septic patients with pneumonia. ( Armstrong, VW; Igonin, AA; Kukes, VG; Oellerich, M; Shipkova, M, 2000) |
"Sepsis was induced by cecal ligation and puncture." | 5.40 | Adenosine, lidocaine and Mg2+ (ALM) induces a reversible hypotensive state, reduces lung edema and prevents coagulopathy in the rat model of polymicrobial sepsis. ( Dobson, GP; Griffin, MJ; Letson, HL, 2014) |
"Lidocaine (Lido) is reported to suppress inflammatory responses and exhibit a therapeutic effect in models of cecal ligation and puncture (CLP)-induced acute lung injury (ALI)." | 3.85 | RAGE deficiency attenuates the protective effect of Lidocaine against sepsis-induced acute lung injury. ( Jiang, X; Li, X; Liao, C; Liu, M; Song, D; Zhang, Z; Zhou, J, 2017) |
"The animals were randomly allocated to one of five groups (n = 8 each): hamsters undergoing sham laparotomy alone and receiving saline infusion (Sham group), those undergoing cecal ligation with puncture (CLP) and receiving an infusion of saline (Sepsis group), those undergoing sham laparotomy and receiving infusion of lidocaine, 2 mg/kg/hr (Sham-LID group), those undergoing CLP and receiving infusion of lidocaine, 1 mg/kg/hr (Sepsis-LID 1 group), and those undergoing CLP and receiving infusion of lidocaine, 2 mg/kg/hr (Sepsis-LID 2 group)." | 3.70 | Lidocaine attenuates sepsis-induced diaphragmatic dysfunction in hamsters. ( Kagawa, T; Kodama, S; Maekawa, N; Mikawa, K; Nishina, K; Obara, H, 2000) |
"These results show that lidocaine attenuates endotoxin-induced alterations in leukocyte-endothelial cell adhesion and macromolecular leakage, which suggests that lidocaine may have a therapeutic role in preventing endothelial damage in sepsis." | 3.69 | Influence of lidocaine on endotoxin-induced leukocyte-endothelial cell adhesion and macromolecular leakage in vivo. ( Bauer, H; Gebhard, MM; Martin, E; Schmidt, H; Schmidt, W, 1997) |
"Lidocaine treatment abrogated chemokine-induced neutrophil arrest and significantly impaired neutrophil transmigration through endothelial cells by inhibition of the protein kinase C-θ while not affecting the selectin-mediated slow leukocyte rolling." | 2.79 | Lidocaine reduces neutrophil recruitment by abolishing chemokine-induced arrest and transendothelial migration in septic patients. ( Berger, C; Hahnenkamp, K; Rossaint, J; Van Aken, H; Westphal, M; Zarbock, A, 2014) |
"The monoethylglycinexylidide (MEGX) test was carried out on days 1-10 after admittance to the intensive care unit." | 2.69 | The monoethylglycinexylidide (MEGX) test as a marker of hepatic dysfunction in septic patients with pneumonia. ( Armstrong, VW; Igonin, AA; Kukes, VG; Oellerich, M; Shipkova, M, 2000) |
"Sepsis was induced by cecal ligation and puncture." | 1.40 | Adenosine, lidocaine and Mg2+ (ALM) induces a reversible hypotensive state, reduces lung edema and prevents coagulopathy in the rat model of polymicrobial sepsis. ( Dobson, GP; Griffin, MJ; Letson, HL, 2014) |
"Chloral hydrate (100mg/kg) was given orally for the induction of moderate to deep sedation 15 minutes before OSC; then the operative field was infiltrated with 1% lidocaine." | 1.39 | Central venous cutdown in neonates: feasibility as a bedside procedure without general anesthesia. ( Hong, SM; Lee, HS; Moon, SB, 2013) |
"Patients with sepsis have severe impairment of cytochrome P450-dependent liver function, which is not influenced by acute changes in hepatosplanchnic blood flow." | 1.31 | Effect of dopamine-induced changes in splanchnic blood flow on MEGX production from lidocaine in septic and cardiac surgery patients. ( Jakob, SM; Rosenberg, PH; Ruokonen, E; Takala, J, 2002) |
"Lidocaine treatment did not alter the hemodynamic measurements and resulted in metabolic acidosis and hypoalbuminemia." | 1.27 | Lidocaine treatment of dogs with Escherichia coli septicemia. ( Hardie, EM; Rakich, PM; Rawlings, CA; Shotts, EB; Waltman, DW, 1988) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 3 (17.65) | 18.7374 |
1990's | 3 (17.65) | 18.2507 |
2000's | 3 (17.65) | 29.6817 |
2010's | 7 (41.18) | 24.3611 |
2020's | 1 (5.88) | 2.80 |
Authors | Studies |
---|---|
Zheng, B | 1 |
Yang, H | 1 |
Zhang, J | 1 |
Wang, X | 1 |
Sun, H | 1 |
Hu, F | 1 |
Li, Q | 1 |
Jiang, L | 1 |
Su, Y | 1 |
Peng, Q | 1 |
Tang, Y | 1 |
Liu, WT | 1 |
He, X | 1 |
Fan, Y | 1 |
Zhu, X | 1 |
Hong, SM | 1 |
Lee, HS | 1 |
Moon, SB | 1 |
Liu, J | 1 |
Zhang, H | 1 |
Qi, Z | 1 |
Zheng, X | 1 |
Berger, C | 1 |
Rossaint, J | 1 |
Van Aken, H | 1 |
Westphal, M | 1 |
Hahnenkamp, K | 1 |
Zarbock, A | 1 |
Wang, HL | 1 |
Xing, YQ | 1 |
Xu, YX | 1 |
Rong, F | 1 |
Lei, WF | 1 |
Zhang, WH | 1 |
Griffin, MJ | 2 |
Letson, HL | 2 |
Dobson, GP | 2 |
Zhang, Z | 1 |
Zhou, J | 1 |
Liao, C | 1 |
Li, X | 1 |
Liu, M | 1 |
Song, D | 1 |
Jiang, X | 1 |
Schmidt, W | 1 |
Schmidt, H | 1 |
Bauer, H | 1 |
Gebhard, MM | 1 |
Martin, E | 1 |
Sakuragi, T | 1 |
Yanagisawa, K | 1 |
Shirai, Y | 1 |
Dan, K | 1 |
Kodama, S | 1 |
Mikawa, K | 1 |
Nishina, K | 1 |
Maekawa, N | 1 |
Kagawa, T | 1 |
Obara, H | 1 |
Igonin, AA | 1 |
Armstrong, VW | 1 |
Shipkova, M | 1 |
Kukes, VG | 1 |
Oellerich, M | 1 |
Jakob, SM | 1 |
Ruokonen, E | 1 |
Rosenberg, PH | 1 |
Takala, J | 1 |
Scholtmeijer, RJ | 1 |
Dzoljic-Danilovic, G | 1 |
Anderson, CT | 1 |
Berde, CB | 1 |
Sethna, NF | 1 |
Pribaz, JJ | 1 |
Hardie, EM | 1 |
Rawlings, CA | 1 |
Shotts, EB | 1 |
Waltman, DW | 1 |
Rakich, PM | 1 |
Eldirini, AH | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Lidocaine For Neuroprotection During Cardiac Surgery[NCT00938964] | 550 participants (Actual) | Interventional | 2009-07-31 | Completed | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
"Center for Epidemiological Studies Depression Scale (CES-D). The CES-D is a 20-item self-report examination designed to measure symptoms of depression. Subjects rate the degree to which they have experienced a range of symptoms of depression, such as I had crying spells and I felt lonely. Scores range from 0 to 60, with higher scores indicating greater depressive symptoms. Scores greater than 16 are typically considered indicative of clinically significant depression." (NCT00938964)
Timeframe: baseline, 1-year
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | -1.27 |
Placebo | -0.89 |
"Center for Epidemiological Studies Depression Scale (CES-D). The CES-D is a 20-item self-report examination designed to measure symptoms of depression. Subjects rate the degree to which they have experienced a range of symptoms of depression, such as I had crying spells and I felt lonely. Scores range from 0 to 60, with higher scores indicating greater depressive symptoms. Scores greater than 16 are typically considered indicative of clinically significant depression." (NCT00938964)
Timeframe: baseline, 6-weeks
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | 0.57 |
Placebo | 0.16 |
To characterize cognitive function over time, while minimizing potential redundancy in the cognitive measures, a factor analysis was performed on the 14 cognitive test scores from baseline. We chose a five-factor solution, which represents 5 cognitive domains: structured verbal memory, unstructured verbal memory, executive function, visual memory and attention/concentration. To quantify overall cognitive function, a baseline cognitive index was first calculated as the mean of the 5 preoperative domain scores. The cognitive index score has a mean of zero, thus any positive score is above the mean, any negative score is below the mean. A continuous change score was then calculated by subtracting the baseline from the 1 year cognitive index. The resulting outcome measure is unbounded with standard deviation of 0.35. A negative change score indicating decline and a positive score indicating improvement (NCT00938964)
Timeframe: 1 year after surgery
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | 0.09 |
Placebo | 0.07 |
To characterize cognitive function over time, while minimizing potential redundancy in the cognitive measures, a factor analysis was performed on the 14 cognitive test scores from baseline. We chose a five-factor solution, which represents 5 cognitive domains: structured verbal memory, unstructured verbal memory, executive function, visual memory and attention/concentration. To quantify overall cognitive function, a baseline cognitive index was first calculated as the mean of the 5 preoperative domain scores. The cognitive index score has a mean of zero, thus any positive score is above the mean, any negative score is below the mean. A continuous change score was then calculated by subtracting the baseline from the 6-week cognitive index. The resulting outcome measure is unbounded with standard deviation of 0.35. A negative change score indicating decline and a positive score indicating improvement. (NCT00938964)
Timeframe: Preoperative to 6 weeks after surgery
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | 0.07 |
Placebo | 0.07 |
"The DASI is a 12-item scale of functional capacity that has been found to correlate well with objective measures of maximal exercise capacity. Items reflect activities of personal care, ambulation, household tasks, sexual function, and recreational activities. Activities done with no difficulty receive scores, which are weighted and summed, for a quantitative measure of functional status. Scores range from 0 to 60; a higher-weighted score indicates better function." (NCT00938964)
Timeframe: baseline, 1-year
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | 6.3 |
Placebo | 6.96 |
"The DASI is a 12-item scale of functional capacity that has been found to correlate well with objective measures of maximal exercise capacity. Items reflect activities of personal care, ambulation, household tasks, sexual function, and recreational activities. Activities done with no difficulty receive scores, which are weighted and summed, for a quantitative measure of functional status. Scores range from 0 to 60; a higher-weighted score indicates better function." (NCT00938964)
Timeframe: baseline, 6-weeks
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | -10.98 |
Placebo | -11.67 |
The National Institutes of Health Stroke Scale (NIHSS) is a 15-item neurologic examination stroke scale used to evaluate the effect of acute cerebral infarction on the levels of consciousness, language, neglect, visual-field loss, extraocular movement, motor strength, ataxia, dysarthria, and sensory loss. A trained observer rates the patent's ability to answer questions and perform activities. Ratings for each item are scored with 3 to 5 grades with 0 as normal, and there is an allowance for untestable items. The range of scores is from 0 (normal) to 42 (profound effect of stroke on patient). (NCT00938964)
Timeframe: baseline, 1-year
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | 0.05 |
Placebo | 0.07 |
The National Institutes of Health Stroke Scale (NIHSS) is a 15-item neurologic examination stroke scale used to evaluate the effect of acute cerebral infarction on the levels of consciousness, language, neglect, visual-field loss, extraocular movement, motor strength, ataxia, dysarthria, and sensory loss. A trained observer rates the patent's ability to answer questions and perform activities. Ratings for each item are scored with 3 to 5 grades with 0 as normal, and there is an allowance for untestable items. The range of scores is from 0 (normal) to 42 (profound effect of stroke on patient). (NCT00938964)
Timeframe: baseline, 6-weeks
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | 0.05 |
Placebo | 0.04 |
The Western perioperative neurologic scale was designed to detect neurologic deficits after cardiac surgery. It includes 14 items classified into eight domains (mentation, speech, cranial nerve function, motor weakness, sensation and cerebellum, reflexes, and gait). Each item is scored from 0 (severe deficit) to3 (normal), and a maximum score of 42 indicates normal neurological function. (NCT00938964)
Timeframe: baseline, 1-year
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | 0.02 |
Placebo | -0.02 |
The Western perioperative neurologic scale was designed to detect neurologic deficits after cardiac surgery. It includes 14 items classified into eight domains (mentation, speech, cranial nerve function, motor weakness, sensation and cerebellum, reflexes, and gait). Each item is scored from 0 (severe deficit) to3 (normal), and a maximum score of 42 indicates normal neurological function. (NCT00938964)
Timeframe: baseline, 6-weeks
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | 0.04 |
Placebo | -0.01 |
"Perceived Social Support Scale: Twelve items indicate how strongly subjects agree that there is a special person who is around when I am in need and my family really tries to help me. Choices range from very strongly disagree to very strongly agree. Items are summed for a range of 12 to 84, with a high score meaning more social support." (NCT00938964)
Timeframe: baseline, 1-year
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | 0.71 |
Placebo | -1.16 |
"Perceived Social Support Scale: Twelve items indicate how strongly subjects agree that there is a special person who is around when I am in need and my family really tries to help me. Choices range from very strongly disagree to very strongly agree. Items are summed for a range of 12 to 84, with a high score meaning more social support." (NCT00938964)
Timeframe: baseline, 6-weeks
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | 1.23 |
Placebo | -0.49 |
"Social Activity: This measure consisted of eight items that indicate the degree of social interaction. Sample items are How often do you talk on the telephone with friends and relatives? and How often do you attend meetings of social groups, clubs, or civic organizations? Scores range from 8 to 32. A lower score indicates more social activity." (NCT00938964)
Timeframe: baseline, 1-year
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | -0.20 |
Placebo | 0.03 |
"Social Activity: This measure consisted of eight items that indicate the degree of social interaction. Sample items are How often do you talk on the telephone with friends and relatives? and How often do you attend meetings of social groups, clubs, or civic organizations? Scores range from 8 to 32. A lower score indicates more social activity." (NCT00938964)
Timeframe: baseline, 6-weeks
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | 0.95 |
Placebo | 1.59 |
"Spielberger State Anxiety Inventory (STAI): The STAI consists of two 20-item scales that measure anxiety. Representative items include statements such as I feel nervous and I feel worried. These items are rated on a 4-point scale, based on how well they describe the patient's current or typical mood, from not at all to very much so. Scores range from 20 to 80, with higher scores indicating greater anxiety." (NCT00938964)
Timeframe: baseline, 1-year
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | -6.70 |
Placebo | -6.39 |
"Spielberger State Anxiety Inventory (STAI): The STAI consists of two 20-item scales that measure anxiety. Representative items include statements such as I feel nervous and I feel worried. These items are rated on a 4-point scale, based on how well they describe the patient's current or typical mood, from not at all to very much so. Scores range from 20 to 80, with higher scores indicating greater anxiety." (NCT00938964)
Timeframe: baseline, 6-weeks
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | -7.12 |
Placebo | -6.31 |
Symptom limitations: Patients were given a list of eight symptoms and asked to rate the degree to which the symptom limited daily activities. The symptoms were angina, shortness of breath, arthritis, back trouble, leg pains, headaches, fatigue, and other. Scores range from 8 to 32, with higher scores indicating greater limitations. (NCT00938964)
Timeframe: baseline, 1-year
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | -1.39 |
Placebo | -1.48 |
Symptom limitations: Patients were given a list of eight symptoms and asked to rate the degree to which the symptom limited daily activities. The symptoms were angina, shortness of breath, arthritis, back trouble, leg pains, headaches, fatigue, and other. Scores range from 8 to 32, with higher scores indicating greater limitations. (NCT00938964)
Timeframe: baseline, 6-weeks
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | -0.67 |
Placebo | -0.8 |
"Cognitive Difficulties Scale: a 39-item scale, is a self-report assessment of perceived problems in long- and short-term memory, concentration, attention, and psycho-motor coordination. Sample items are I forget errands I planned to do and I fail to recognize people I know. Scores range from 39 to 164, with higher scores indicating greater cognitive difficulty." (NCT00938964)
Timeframe: baseline, 1-year
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | -0.46 |
Placebo | -1.02 |
"Cognitive Difficulties Scale: a 39-item scale, is a self-report assessment of perceived problems in long- and short-term memory, concentration, attention, and psycho-motor coordination. Sample items are I forget errands I planned to do and I fail to recognize people I know. Scores range from 39 to 164, with higher scores indicating greater cognitive difficulty." (NCT00938964)
Timeframe: baseline, 6-weeks
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | -3 |
Placebo | -3.21 |
"Duke Older Americans Resources and Services Procedures- Instrumental Activities of Daily Living (OARS-IADL): This measure contains six items that assess the ability to perform important tasks for daily living (e.g., Could you prepare your own meals? Could you drive a car?). Scores range from 6 to 24. Higher scores indicate increasing difficulty in engaging in daily activities." (NCT00938964)
Timeframe: baseline, 1-year
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | -0.15 |
Placebo | -0.31 |
"Duke Older Americans Resources and Services Procedures- Instrumental Activities of Daily Living (OARS-IADL): This measure contains six items that assess the ability to perform important tasks for daily living (e.g., Could you prepare your own meals? Could you drive a car?). Scores range from 6 to 24. Higher scores indicate increasing difficulty in engaging in daily activities." (NCT00938964)
Timeframe: baseline, 6-weeks
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | 2.46 |
Placebo | 2.1 |
To characterize cognitive function over time, while minimizing potential redundancy in the cognitive measures, a factor analysis was performed on the 14 cognitive test scores from baseline. We chose a five-factor solution, which represents 5 cognitive domains: structured verbal memory, unstructured verbal memory, executive function, visual memory and attention/concentration. Each domain score is normally distributed with a mean of zero. A change score was calculated for each domain by subtracting the baseline from the 6-week score. A dichotomous outcome variable of post-operative cognitive deficit was defined as a decline of ≥1 standard deviation in 1 or more of the 5 domains. (NCT00938964)
Timeframe: Preoperative to 6 weeks after surgery
Intervention | Participants (Count of Participants) |
---|---|
Lidocaine | 87 |
Placebo | 83 |
The Medical Outcomes Study 36-Item Short Form Health Survey (SF-36): The SF-36 was designed to measure general health status. Two scales were used: Work Activities (four items) and General Health (one item). For the work activities scale, the reported score was the sum of four questions, each with values ranging from 1 to 4, the total score could range from 4 to 16. A higher score on Work Activities indicates more health-related problems For the general health question, the patients ranked their health from Excellent (1) to poor (5), the scale ranged from 1 to 5 with 1 being best health and 5 being worst. A high score in General Health indicates poorer health state. (NCT00938964)
Timeframe: baseline, 1-year
Intervention | units on a scale (Mean) | |
---|---|---|
1 year Change Work Activities | 1 year Change General health perception | |
Lidocaine | -1.37 | -0.28 |
Placebo | -1.42 | -0.43 |
The Medical Outcomes Study 36-Item Short Form Health Survey (SF-36): The SF-36 was designed to measure general health status. Two scales were used: Work Activities (four items) and General Health (one item). For the work activities scale, the reported score was the sum of four questions, each with values ranging from 1 to 4, the total score could range from 4 to 16. A higher score on Work Activities indicates more health-related problems For the general health question, the patients ranked their health from Excellent (1) to poor (5), the scale ranged from 1 to 5 with 1 being best health and 5 being worst. A high score in General Health indicates poorer health state. (NCT00938964)
Timeframe: baseline, 6-weeks
Intervention | units on a scale (Mean) | |
---|---|---|
6-Week Change Work activities | 6-Week Change General health perception | |
Lidocaine | 2.71 | -0.004 |
Placebo | 3 | -0.03 |
Paired jugular venous and radial arterial blood samples were drawn at baseline, cross-clamp removal, end of cardiopulmonary bypass, and 6 hours post cross-clamp removalime points and analyzed by fluorescence-activated cell sorting to identify activated platelets. Transcerebral activation gradients were calculated by subtracting arterial values from venous values and were compared between groups (NCT00938964)
Timeframe: Baseline to 6 hours post cross-clamp removal
Intervention | Mean linear fluorescence intensity-MLFI (Mean) | |||
---|---|---|---|---|
Baseline | Cross-clamp removal | End of Bypass | 6 hours post cross-clamp removal | |
Lidocaine | -0.15 | 0.02 | -0.73 | -0.10 |
Placebo | -0.43 | -0.73 | -0.40 | 0.19 |
Paired jugular venous and radial arterial blood samples were drawn at baseline, cross-clamp removal, end of cardiopulmonary bypass, and 6 hours post cross-clamp removalime points and analyzed by fluorescence-activated cell sorting to identify activated platelets. Transcerebral activation gradients were calculated by subtracting arterial values from venous values and were compared between groups (NCT00938964)
Timeframe: Baseline to 6 hours post cross-clamp removal
Intervention | Mean linear fluorescence intensity-MLFI (Mean) | |||
---|---|---|---|---|
Baseline | Cross-clamp removal | End of Bypass | 6 hours post cross-clamp removal | |
Lidocaine | -4.22 | -2.46 | -0.34 | 1.21 |
Placebo | -0.04 | 1.83 | 2.64 | 0.54 |
Paired jugular venous and radial arterial blood samples were drawn at baseline, cross-clamp removal, end of cardiopulmonary bypass, and 6 hours post cross-clamp removal and analyzed by fluorescence-activated cell sorting to identify activated platelets. Transcerebral activation gradients were calculated by subtracting arterial values from venous values and were compared between groups (NCT00938964)
Timeframe: Baseline to 6 hours post cross-clamp removal
Intervention | Mean linear fluorescence intensity-MLFI (Mean) | |||
---|---|---|---|---|
Baseline | Cross-clamp removal | End of Bypass | 6 hours post cross-clamp removal | |
Lidocaine | -2.02 | 0.56 | 0.58 | 1.04 |
Placebo | -0.08 | 0.17 | 1.19 | -0.68 |
Paired jugular venous and radial arterial blood samples were drawn at baseline, cross-clamp removal, end of cardiopulmonary bypass, and 6 hours post cross-clamp removalime points and analyzed by fluorescence-activated cell sorting to identify activated platelets. Transcerebral activation gradients were calculated by subtracting arterial values from venous values and were compared between groups (NCT00938964)
Timeframe: Baseline to 6 hours post cross-clamp removal
Intervention | Mean linear fluorescence intensity-MLFI (Mean) | |||
---|---|---|---|---|
Baseline | Cross-clamp removal | End of Bypass | 6 hours post cross-clamp removal | |
Lidocaine | -0.03 | 0.03 | 0.33 | 0.37 |
Placebo | 0.35 | 0.43 | 0.05 | 0.27 |
3 trials available for lidocaine and Blood Poisoning
Article | Year |
---|---|
Lidocaine reduces neutrophil recruitment by abolishing chemokine-induced arrest and transendothelial migration in septic patients.
Topics: Anesthetics, Local; Cell Adhesion Molecules; Cell Cycle Checkpoints; Cell Membrane; Chemokines; Fema | 2014 |
The monoethylglycinexylidide (MEGX) test as a marker of hepatic dysfunction in septic patients with pneumonia.
Topics: Adult; Aged; Biomarkers; Cytokines; Female; Humans; Lidocaine; Liver; Male; Middle Aged; Pneumonia; | 2000 |
Effectiveness of epinephrine in local anesthetic solutions on the bacteremia following dental extraction.
Topics: Adolescent; Adult; Aged; Anesthetics, Local; Clinical Trials as Topic; Epinephrine; Humans; Lidocain | 1968 |
14 other studies available for lidocaine and Blood Poisoning
Article | Year |
---|---|
Lidocaine Alleviates Sepsis-Induced Acute Lung Injury in Mice by Suppressing Tissue Factor and Matrix Metalloproteinase-2/9.
Topics: Acute Lung Injury; Animals; Gene Expression Regulation; Lidocaine; Lipopolysaccharides; Male; Matrix | 2021 |
Central venous cutdown in neonates: feasibility as a bedside procedure without general anesthesia.
Topics: Administration, Oral; Anesthesia, Local; Anesthetics, Local; Catheterization, Central Venous; Chlora | 2013 |
Lidocaine protects against renal and hepatic dysfunction in septic rats via downregulation of Toll‑like receptor 4.
Topics: Animals; Disease Models, Animal; Down-Regulation; Interleukin-6; Kidney; Lidocaine; Lipopolysacchari | 2014 |
The protective effect of lidocaine on septic rats via the inhibition of high mobility group box 1 expression and NF-κB activation.
Topics: Animals; HMGB1 Protein; Lidocaine; Male; NF-kappa B; Peroxidase; Protein Transport; Rats; Rats, Wist | 2013 |
Adenosine, lidocaine and Mg2+ (ALM) induces a reversible hypotensive state, reduces lung edema and prevents coagulopathy in the rat model of polymicrobial sepsis.
Topics: Adenosine; Animals; Blood Coagulation Disorders; Disease Models, Animal; Drug Therapy, Combination; | 2014 |
Small-Volume Adenosine, Lidocaine, and Mg2+ 4-Hour Infusion Leads to 88% Survival after 6 Days of Experimental Sepsis in the Rat without Antibiotics.
Topics: Acidosis; Adenosine; Animals; Anti-Bacterial Agents; C-Reactive Protein; Cytokines; Disease Models, | 2016 |
RAGE deficiency attenuates the protective effect of Lidocaine against sepsis-induced acute lung injury.
Topics: Acute Lung Injury; Animals; Gene Knockout Techniques; HMGB1 Protein; Inflammation; Lidocaine; MAP Ki | 2017 |
Influence of lidocaine on endotoxin-induced leukocyte-endothelial cell adhesion and macromolecular leakage in vivo.
Topics: Anesthetics, Local; Animals; Blood Cell Count; Capillary Permeability; Cell Adhesion; Endothelium, V | 1997 |
Growth of Escherichia coli in propofol, lidocaine, and mixtures of propofol and lidocaine.
Topics: Anesthetics, Intravenous; Anesthetics, Local; Anti-Bacterial Agents; Colony Count, Microbial; Drug C | 1999 |
Lidocaine attenuates sepsis-induced diaphragmatic dysfunction in hamsters.
Topics: Anesthetics, Local; Animals; Cricetinae; Diaphragm; Electric Stimulation; Lidocaine; Male; Malondial | 2000 |
Effect of dopamine-induced changes in splanchnic blood flow on MEGX production from lidocaine in septic and cardiac surgery patients.
Topics: Adult; Aged; Dopamine; Female; Humans; Lidocaine; Male; Middle Aged; Sepsis; Splanchnic Circulation; | 2002 |
Disinfecting effect of a disposable lubricant during cystoscopy.
Topics: Child; Chlorhexidine; Cross Infection; Cystoscopy; Disinfectants; Drug Combinations; Female; Humans; | 1990 |
Meningococcal purpura fulminans: treatment of vascular insufficiency in a 2-yr-old child with lumbar epidural sympathetic blockade.
Topics: Anesthesia, Epidural; Autonomic Nerve Block; Bupivacaine; Child, Preschool; Disseminated Intravascul | 1989 |
Lidocaine treatment of dogs with Escherichia coli septicemia.
Topics: Animals; Blood Pressure; Cardiac Output; Dog Diseases; Dogs; Escherichia coli Infections; Lidocaine; | 1988 |